These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Tsao YC; Chen TY; Wang LA; Lee CC; Lee WA; Hsu SM; Lai CC; Shao SC; Hung JH; Lai EC BioDrugs; 2023 Nov; 37(6):843-854. PubMed ID: 37676536 [TBL] [Abstract][Full Text] [Related]
10. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437 [TBL] [Abstract][Full Text] [Related]
11. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab. Spooner K; Fraser-Bell S; Hong T; Chang A Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950 [TBL] [Abstract][Full Text] [Related]
12. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. Cai S; Bressler NM Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425 [TBL] [Abstract][Full Text] [Related]
14. Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab. Wood EH; Karth PA; Moshfeghi DM; Leng T Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):950-4. PubMed ID: 26469235 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further? Uludag G; Hassan M; Matsumiya W; Pham BH; Chea S; Trong Tuong Than N; Doan HL; Akhavanrezayat A; Halim MS; Do DV; Nguyen QD Expert Opin Biol Ther; 2022 Oct; 22(10):1275-1291. PubMed ID: 35818801 [TBL] [Abstract][Full Text] [Related]
16. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications. Blaha GR; Brooks NO; Mackel CE; Pani A; Stewart AP; Price LL; Barouch FC; Chang J; Marx JL Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942 [TBL] [Abstract][Full Text] [Related]
17. Intravitreal anti-vascular endothelial growth factor injections in pregnancy and breastfeeding: a case series and systematic review of the literature. Ong AY; Kiire CA; Frise C; Bakr Y; de Silva SR Eye (Lond); 2024 Apr; 38(5):951-963. PubMed ID: 37980398 [TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis. Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915 [TBL] [Abstract][Full Text] [Related]
19. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network. Krick TW; Bressler NM Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861 [TBL] [Abstract][Full Text] [Related]
20. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA; JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]